

Nephrology II Panel

Editorial Board Liaison

Michelle M. Richardson, Pharm.D., FCCP, BCPS
Clinical Associate Professor
 Northeastern University
Special and Scientific Staff

William B. Schwartz, M.D. Division of Nephrology
 Tufts—New England Medical Center
Assistant Professor of Medicine
 Tufts University School of Medicine
 Boston, Massachusetts

Authors

Linda Awdishu, BScPhm, MAS
Pharmacist Specialist
 Abdominal Transplantation
Manager
 Chronic Kidney Disease Clinic
 Department of Pharmacy
 University of California San Diego Medical Center
 San Diego, California

Scott Bolesta, Pharm.D.
Assistant Professor
 Department of Pharmacy Practice
 Nesbitt College of Pharmacy and Nursing
 Wilkes University
 Wilkes-Barre, Pennsylvania

Edward F. Foote, Pharm.D., FCCP, BCPS
Associate Professor and Chair of Pharmacy Practice
 Department of Pharmacy Practice
 Nesbitt College of Pharmacy and Nursing
 Wilkes University
 Wilkes-Barre, Pennsylvania

Ravindra L. Mehta, M.D., DM, FACP, FASN
 Professor of Clinical Medicine,
 Associate Chair Clinical Affairs
 Department of Medicine – Division of Nephrology
 University of California San Diego
 San Diego California

Sarah R. Tomasello, Pharm.D., BCPS
Clinical Assistant Professor
 Rutgers, The State University of New Jersey
Clinical Specialist-Nephrology
 Robert Wood Johnson University Hospital
 New Brunswick, New Jersey

Reviewers

The American College of Clinical Pharmacy and the authors would like to thank the following individuals for their careful review of the Book 2 chapters:

Nicola G. Dahl, Pharm.D.
Medical Writer
 Kanab, Utah

Renee M. DeHart, Pharm.D., BCPS
Professor
 Department of Pharmacy Practice
 Samford University
 Birmingham, Alabama

Emilie L. Karpiuk, Pharm.D., BCPS, BCOP
Pharmacy Clinical Manager
 Department of Pharmacy
 St. Joseph Regional Medical Center/Cardinal Health Inc.
 Milwaukee, Wisconsin

Bone Metabolism and Disease in Chronic Kidney Disease

Joanna Q. Hudson, Pharm.D., BCPS
Associate Professor
 Department of Clinical Pharmacy
Assistant Professor
 Department of Medicine (Nephrology)
 Department of Clinical Pharmacy
 The University of Tennessee
 Memphis, Tennessee

Lisa C. Hutchison, Pharm.D., MPH, BCPS
Associate Professor
 Pharmacy Practice
 University of Arkansas for Medical Sciences
 Little Rock, Arkansas

Contrast-Induced Nephropathy

Ted Walton, Pharm.D., BCPS
Clinical Pharmacist Specialist – Nephrology
 Pharmacy and Drug Information
 Grady Health System
 Atlanta, Georgia

Nephrology II Panel

Adam B. Jackson, Pharm.D., BCPS
Clinical Pharmacy Specialist in Infectious Diseases
Pharmacy Department
Kaiser Permanente Colorado
Clinical Assistant Professor
School of Pharmacy
University of Colorado
Denver, Colorado

Drug Issues in Renal Replacement Therapies

Linda Gore Martin, Pharm.D., MBA, BCPS
Associate Professor, Social and Administrative Pharmacy
University of Wyoming School of Pharmacy
Laramie, Wyoming

Bruce A. Mueller, Pharm.D., FCCP, BCPS
Chair and Professor
Department of Clinical Sciences
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Disclosure of Potential Conflicts of Interest

Consultancies: Rita Alloway (Astellas Pharma Inc., Wyeth, Roche, Genzyme); Linda Awdishu (Dialysis Solutions, Inc.) Scott Bolesta (Blue Cross of Northeastern PA); Judy W.M. Cheng (Scios Pharmaceuticals, sanofi-aventis); Thomas Dowling (Gout and Uric Acid Education Society; Shire Laboratories, OBI); Teresa S. Dunsworth (Medicaid P&T Board; West Virginia University Hospitals P&T Committee); Robert Dupuis (Nabi Biopharmaceuticals, Astellas Pharma Inc.); Edward Foote (Kenyon & Kenyon, Scios Pharmaceuticals, ETHOS Health Communications, Roche); Joanna Hudson (Abbott Renal Care) Anne Hume (New England Research Institute, Pharmacotherapy Consultants of New England); Linda G. Martin (Albany County Family Planning, Wyoming Medicaid Drug Utilization, Downtown Clinic – Laramie, WY, Wyoming Society of Health-System Pharmacy); Gary Matzke (American College of Clinical Pharmacology, ASHP, AACP); Michelle M. Richardson (National Kidney Foundation, Agency for Health Care Research/Centers for Medicare and Medicaid Services, Amgen); Jennifer Trofe (Lexi-Comp); Lori Wazny (Ortho-Biotech); Nicole Weimert (ACCP); Eric T. Wittbrodt (GSK/Adolor).

Stock Ownership: G. mark Baillie (Pfizer); Katherine H. Chessman (Proctor and Gamble, stock owned by spouse or significant other); Gary Matzke (ICOS); Michelle M. Richardson (TEI Biosciences Inc., stock owned by spouse or significant other).

Royalties: Gilbert Burckart (University of Pittsburgh); Gary Matzke (McGraw-Hill).

Grants: Rita Alloway (Bristol Myers Squibb, Novartis, Isotechnika, Y's Therapeutics, Idun Pharmaceuticals, Fujisawa Healthcare Incorporated, Astellas Pharma Inc., SangStat Medical Corporation, Wyeth Ayerst, NIH, Roche, Novartis, Genzyme); Linda Awdishu (Roche); Gilbert Burckart (NIH); Thomas Dowling (NovaCardia, NIH, ACCP); Edward Foote (Genzyme); Joanna Hudson (ACCP, Watson Pharmaceuticals); Anne Hume (National Library of Medicine, Bureau of Health Professions, Agency for Healthcare Research and Quality); Lisa Hutchison (Pfizer, Ortho-Biotech, Beverly Enterprises); Linda G. Martin (State of Wyoming Department of Health Aging Division); Bruce Mueller (Cubist, Merck); Kari Olson (ACCP, Heart and Stroke Foundation of Canada, Kaiser Permanente of Colorado); Michelle M. Richardson (QualityMetric and Tufts-New England Medical Center); Jennifer Trofe (Dialysis Clinic International); Eric T. Wittbrodt (Ortho-Biotech, Centocor).

Honoraria: Rita Alloway (Astellas Pharma Inc., Roche, Wyeth Ayerst); Linda Awdishu (American Regent); Judy W.M. Cheng (Scios Pharmaceuticals, Millennium Pharmaceuticals); Katherine H. Chessman (Pfizer); Thomas Dowling (Abbott Labs); Edward Foote (American Regent, Amgen); Joanna Hudson (Abbott Renal Care, Watson Pharmaceuticals); Bruce Mueller (Amgen); Michelle M. Richardson (Amgen); Lori Wazny (Roche); Eric T. Wittbrodt (GSK/Adolor, Amgen, Ortho-Biotech, LP).

Other: Todd P. Semla (spouse or significant other employed by Abbott); Eric T. Wittbrodt (Tap Pharmaceuticals).